Katherine E.
- Country
- Italy
- Department
- UOC Endocrinologia e Malattie del Metabolismo
Research Overview
- Phase III Randomized Open‑Label Trial Evaluating Elecoglipron Versus Oral Semaglutide for Glycemic Control in Adults with Type 2 Diabetes Mellitus
- Evaluation of the Efficacy and Safety of Semaglutide with Reduced-Dose Insulin Glargine Versus Titrated Insulin Glargine in Type 2 Diabetes with Overweight
- Evaluation of Vicadrostat (BI 690517) and Empagliflozin Efficacy and Safety in Type 2 Diabetes, Hypertension, and Cardiovascular Disease Patients
Data & Insights
Has run more than one trial at 31 of 511 partner sites.
Specializations
Diabetes Management
The investigator specializes in the treatment of Type 2 Diabetes Mellitus, with particular focus on innovative therapeutic approaches for patients with overweight conditions.
- Glycemic Control Optimization
- Insulin Management Strategies
- GLP-1 Receptor Agonist Therapies
Research interests include the integration of injectable diabetes medications and their effects on glycemic control.
Cardiovascular Risk Management
Focuses on investigating the relationship between diabetes treatments and cardiovascular outcomes in high-risk patients.
- Cardiovascular Event Prevention
- Major Adverse Cardiac Events
- Cardiovascular Risk Assessment
Explores the impact of diabetes therapeutic agents on cardiovascular mortality and morbidity.
Metabolic Health
Investigates the intersection of weight management and diabetes control through advanced therapeutic approaches.
- Metabolic Disease Management
- Weight Control Strategies
- Combined Therapy Approaches
Studies the effectiveness of combined treatment modalities in managing metabolic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.